Abstract:When assembled in multiprotein polycomb repressive complexes (PRCs), highly evolutionary conserved polycomb group (PcG) proteins epigenetically control gene activity. Although the composition of PRCs may vary considerably, it is well established that the embryonic ectoderm development (EED) 1, suppressor of zeste (SUZ) 12, and methyltransferase enhancer of zeste (EZH2)-containing complex, PRC2, which is abundant in highly proliferative cells (including cancer cells), establishes a repressive methylation mark on histone 3 (H3K27me3). From the perspective of molecular cancer pathogenesis, this effect, when directed towards a promoter of tumor suppressor genes, represents pro-tumorigenic effect. This mode of action was shown in several cancer models. However, EZH2 function extends beyond this scenario. The highly specific cellular background, related to the origin of cell and numerous external stimuli during a given time-window, may be the trigger for EZH2 interaction with other proteins, not necessarily histones. This is particularly relevant for cancer.This review provides a critical overview of the evolutional importance of PRC and discusses several important aspects of EZH2 functioning within PRC. The review also deals with mutational studies on EZH2. Due to the existence of several protein (and messenger RNA (mRNA)) isoforms, these mutations were stratified, using the protein sequence which is considered canonical. This approach showed that there is an urgent need for the uniformed positioning of currently known EZH2 mutations (somatic—in tumors, as well as germline mutations in the Weaver’s syndrome).Finally, we discuss EZH2 function with respect to amount of trimethylated H3K27, in a specific cellular milieu, through presenting the most recent data related to EZH2-H3K27m3 relationship in cancer. All these points are significant in considering EZH2 as a therapeutic target.

Polycomb Directed Cell Fate Decisions in Development and Cancer

Loss of the Polycomb group gene polyhomeotic induces non-autonomous cell overproliferation.

The roles of Polycomb repressive complexes in mammalian development and cancer

Polycomb Repressor Complex: Its Function in Human Cancer and Therapeutic Target Strategy.

Polycomb genes and cancer: Time for clinical application?

Polycomb Group (pcg) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications

Kdm2b Maintains Murine Embryonic Stem Cell Status by Recruiting PRC1 Complex to CpG Islands of Developmental Genes

Polycomb Group Proteins and Their Roles in Carcinogenesis

The Polycomb complex PRC2 and its mark in life

Polycomb-Like Proteins in Gene Regulation and Cancer

Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background

Polycomb-mediated histone modifications and gene regulation

Epigenetic regulation by polycomb group complexes: focus on roles of CBX proteins

Polycomb function in early mouse development

Polycomb Genes, Mirna, and Their Deregulation in B-cell Malignancies.

One, Two, Three: Polycomb Proteins Hit All Dimensions of Gene Regulation

Gene Silencing by the Polycomb Group Proteins and Associations with Cancer

Polycomb Repressive Complex 2 is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer

Polycomb Group Genes As the Key Regulators in Gene Silencing

Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction

PRC2 Promotes Canalisation During Endodermal Differentiation